Loading company…
Qgenetics develops small-molecule drugs using data and artificial intelligence.
Qgenetics uses big data and artificial intelligence to develop small-molecule drugs. Its QG3030 candidate is being developed for osteoporosis and fractures, including local use during fracture surgery and potential oral use. Founded in 2016, it is based in Seoul, South Korea. In April 2021, it raised KRW 3 billion from LSK Investment and Magna Investments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in